Medically Reviewed & Authored by: George King
R&D Manager & Emergency Preparedness Specialist at Fitiger Life LLC.
George specializes in non-clinical intervention systems and institutional safety protocols.
The current EasyPumpVac FAC-01 biological-evaluation package covers three standard endpoints: in vitro cytotoxicity, intracutaneous irritation, and skin sensitization. The table below keeps the report scope and core findings easy to skim.
|
Report No. |
Endpoint |
Key Reported Result |
Conclusion |
|
CY2506049S-6 |
In vitro cytotoxicity |
Morphology grade 1; viability not less than 70% versus blank control |
No potential cytotoxicity |
|
CY2506049S-4 |
Intracutaneous irritation |
0.00 final score for both polar and non-polar extracts |
Meets irritation test requirements |
|
CY2506049S-5 |
Skin sensitization |
0% positive challenge incidence rate |
Did not cause skin sensitization |
Most people looking at an airway-clearance device start with the obvious question: would it help in an emergency? From our side, there is a more basic question that comes first: what do we know about the materials that may come into contact with the body?
For EasyPumpVac FAC-01, our current third-party biological-evaluation package covers three standard endpoints: in vitro cytotoxicity, intracutaneous irritation, and skin sensitization. In the uploaded reports, the cytotoxicity study concluded that the sample extract had no potential cytotoxicity; the irritation study recorded a final score of 0.00 for both polar and non-polar extracts against an acceptance criterion of not greater than 1.0; and the sensitization study concluded that the sample did not cause skin sensitization, with a positive challenge incidence rate of 0%. The reports identify the sample as FAC-01, batch 25050801, production date 2025-05-08, and expiry 2027-05-07.
That is meaningful evidence for material-contact safety under the stated test conditions. It does not mean every other safety, performance, or regulatory question has been answered by these three reports alone. FDA’s current biocompatibility framework is built around the nature of body contact and contact duration, not around a single one-size-fits-all package for every device.
EasyPumpVac is designed to interface with the face and mouth area during use. For that kind of product, material-contact safety is not a footnote. It is one layer of the broader product-safety story.
FDA’s biocompatibility guidance, built around ISO 10993-1, evaluates devices according to what part of the body they contact and for how long. That is why biological evaluation matters for a body-contacting device like this. At the same time, favorable biocompatibility results do not replace other evidence such as usability, labeling, performance testing, training, and emergency instructions.
The uploaded reports identify the sample as a manual negative-pressure suction device, model FAC-01, non-sterile, intended to use negative pressure to remove gas or solid matter from the throat. The three reports cover CY2506049S-6 (in vitro cytotoxicity), CY2506049S-4 (intracutaneous irritation), and CY2506049S-5 (skin sensitization).
All three reports were issued by Sitande Science and Technology (Qingdao), and the summaries state the work was performed within the lab’s CMA and CNAS accredited scope.
Cytotoxicity testing asks a focused question: do material extracts damage cells in the test system?
In CY2506049S-6, the study was performed under GB/T 16886.5-2017 and GB/T 16886.12-2023 using the MTT method. The report states that the 100% test extract had a morphology grade of 1, and that cell viability relative to the blank control was not less than 70%. The acceptance logic in the report says morphology grades greater than 2 are considered cytotoxic, and viability below 70% indicates potential cytotoxicity. The report conclusion states that the sample extract had no potential cytotoxicity.
That is the right way to read the result: under the stated test conditions, the material extract did not show the kind of cell-damaging signal this screening method is designed to flag.
Irritation testing asks a different question: do the extracts provoke a localized irritation response?
In CY2506049S-4, the study was performed under GB/T 16886.23-2023 and GB/T 16886.12-2023. The report states that both the polar extract and the non-polar extract had a final intracutaneous reaction score of 0.00. The acceptance criterion in the report was not greater than 1.0, and the conclusion states that the sample met the intracutaneous irritation test requirements. The report also describes the extraction setup: polar extraction with 0.9% sodium chloride injection and non-polar extraction with cottonseed oil.
In plain language, that means the extracts did not show an irritation signal in the stated intracutaneous model under the reported conditions.
Sensitization asks yet another question: does the tested material show the potential to trigger an allergy-like sensitization response after induction and challenge?
In CY2506049S-5, the testing was performed under GB/T 16886.10-2024 and GB/T 16886.12-2023 using the maximization method in guinea pigs. The report states that neither the polar extract nor the non-polar extract caused a skin sensitization response, and that the positive challenge incidence rate was 0%. The conclusion states that the sample did not cause skin sensitization.
That supports the sensitization portion of the biological evaluation. The careful wording matters here: the report supports a non-sensitizing result under the stated test conditions. It does not justify turning the product into a blanket ‘hypoallergenic for everyone’ claim.
Cytotoxicity, irritation, and sensitization are not the same biological question.
Cytotoxicity looks for harmful effects on cells. Irritation looks for a localized inflammatory response. Sensitization looks for an allergy-like response after exposure and challenge. FDA’s ISO 10993-based framework is built around selecting biological endpoints according to contact type and contact duration, which is why it makes sense to read these endpoints separately instead of blurring them into one vague ‘safe materials’ claim.
That separation is important for readers too. A strong technical article should help people understand which question each report answers.
These reports support several clear, readable statements.
The FAC-01 material system showed no potential cytotoxicity under the stated in vitro test conditions. The FAC-01 extracts showed 0.00 irritation scores for both polar and non-polar intracutaneous testing under the stated conditions. The FAC-01 extracts also showed no sensitization response in the stated guinea pig sensitization study, with a positive challenge incidence rate of 0%.
These reports do not, by themselves, prove every other safety or performance aspect of the product; FDA clearance or approval on their own; that every user in every situation will never experience any reaction; or that the product can replace training, instructions, or established choking-response steps.
That kind of boundary-setting does not weaken the article. It strengthens trust.
A family buyer may never want to read a lab report cover to cover. A school buyer may only care whether the body-contacting material story is based on evidence or on adjectives.
These reports let us answer that question more responsibly. Instead of saying ‘the materials are safe’ and stopping there, we can point to three specific biological-evaluation endpoints, three report numbers, and three stated conclusions. For institutional readers, that is more useful than a slogan. For families, it is easier to trust.
This also fits the broader 2026 regulatory context without overclaiming. FDA’s March 2026 de novo order places the generic device type suction anti-choking device as a second-line treatment’ under 21 CFR 874.5400, and the special controls include non-clinical performance testing to address adverse tissue reaction and durability risks. That does not mean one blog post should turn biocompatibility reports into a blanket ‘compliance’ statement. It means these reports add relevant third-party material-contact evidence to the broader product-evaluation picture.
Biocompatibility testing is one layer of safety. It is not the whole emergency-response story.
FDA continues to encourage the public to follow established choking rescue protocols first, and public Red Cross guidance continues to teach 5 back blows followed by 5 abdominal thrusts for responsive adults and children. EasyPumpVac’s material-contact results belong in the engineering evidence conversation, not in place of first-aid response steps.
EasyPumpVac FAC-01 now has third-party report support across three standard biological-evaluation endpoints: cytotoxicity, irritation, and sensitization. The reports show a non-cytotoxic summary result, 0.00 intracutaneous irritation scores for both extract types, and no sensitization response with 0% positive challenge incidence under the stated conditions.
That supports the material-contact side of the EasyPumpVac safety story. It does not replace performance evidence, usability evidence, first-aid training, or device instructions. That is not a weakness in the article. It is what credible engineering communication looks like.
What biocompatibility tests were completed for EasyPumpVac?
The current report set covers in vitro cytotoxicity, intracutaneous irritation, and skin sensitization for FAC-01.
Did EasyPumpVac pass cytotoxicity testing?
The cytotoxicity report states a morphology grade of 1, viability not less than 70% versus the blank control, and a conclusion of no potential cytotoxicity.
What were the irritation results?
The irritation report states a final score of 0.00 for both the polar and non-polar extracts, with an acceptance criterion of not greater than 1.0.
Did sensitization testing show any allergy-like response?
No. The sensitization report states that the polar and non-polar extracts did not cause skin sensitization, and that the positive challenge incidence rate was 0%.
Does this mean the product is FDA-approved just because these tests were favorable?
No. These reports support one part of the biological safety assessment. They do not, by themselves, establish FDA clearance, approval, or every broader regulatory conclusion.
Does this change what to do in a choking emergency?
No. Follow established choking rescue protocols first. FDA and the Red Cross continue to place those steps first in the emergency-response sequence.
This article discusses laboratory biocompatibility findings for the Fitiger EasyPumpVac (FAC-01) based on official reports. It is intended for engineering, educational, and preparedness purposes only. Lab results support material-contact safety evaluation under the stated conditions, but they do not guarantee clinical outcomes in an emergency. Follow established choking rescue protocols first, call 911 immediately, and use second-line suction devices only in accordance with their validated IFU.
Fitiger Scientific Evidence page
Technical report access and supporting engineering materials.
FDA ISO 10993-1 guidance
Biological evaluation based on contact type and contact duration.
FDA de novo order (DEN250012)
Second-line device context under 21 CFR 874.5400.
FDA safety communication on choking rescue protocols
Public guidance on anti-choking devices and first-line choking response.
American Red Cross adult and child choking guidance
Public first-response reference for responsive choking emergencies.
